Zai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by China’s NMPA

May 12, 2024

Read More

Zai Lab Announces First Quarter 2024 Financial Results and Recent Corporate Updates

May 08, 2024

Read More

Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024

Apr 15, 2024

Read More

Zai Lab Statement on Executive Management Team’s Agreement on Share Activities

Apr 11, 2024

Read More

Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs

Apr 02, 2024

Read More

Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Apr 01, 2024

Read More

Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer

Mar 27, 2024

Read More

Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors

Mar 13, 2024

Read More